NCT00752596

Compassionate Use Study of 125 mg Per Day of Azimilide Dihydrochloride in One Patient

Compassionate Use Study to Assess the Long Term Safety of 125 mg Per Day of Oral Azimilide Dihydrochloride in One Patient Following Termination of the SHIELD Open-label Study 2001060

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 1 (actual)
• Sponsor: Forest Laboratories · Industry
• Sex: Male
• Age: —
• Healthy volunteers: Not accepted

Summary

This is an open-label, long term compassionate use study of 125 mg per day of azimilide 2HCl in a patient who completed two other protocols (2000098 and 2001060.

Conditions

• Congestive Heart Failure

Interventions

Type	Name	Description
DRUG	Azimilide 2HCl	One tablet of 125 mg/day azimilide 2HCl, taken until the study is terminated

Timeline

• Start date: 2005-09-01
• Primary completion: 2006-07-01
• Completion: 2006-07-01
• First posted: 2008-09-15
• Last updated: 2017-02-01

Locations

1 site across 1 country: United States